Literature DB >> 21259073

Consensus interferon: tailored therapy and the impact of adherence.

Stevan A Gonzalez.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21259073     DOI： 10.1007/s10620-011-1563-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  36 in total

1.  A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.

Authors:  Giovanna Fattovich; Irene Zagni; Eliseo Minola; Martina Felder; Pierangelo Rovere; Antonio Carlotto; Sergio Suppressa; Anna Miracolo; Claudio Paternoster; Caterina Rizzo; Angelo Rossini; Paolo Benedetti; Marco Capanni; Chiara Ferrara; Paolo Costa; Tosca Bertin; Maurizio Pantalena; Lorenzo Lomonaco; Chiara Scattolini; Giuseppe Mazzella; Massimo Giusti; Sergio Boccia; Stefano Milani; Renato Marin; Maria Lisa Ribero; Alessandro Tagger
Journal:  J Hepatol       Date:  2003-11       Impact factor: 25.083

2.  The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients.

Authors:  P J Pockros; R Reindollar; J McHutchinson; R Reddy; T Wright; D G Boyd; L B Wilkes
Journal:  J Viral Hepat       Date:  2003-01       Impact factor: 3.728

3.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

Authors:  José M Sánchez-Tapias; Moisés Diago; Pedro Escartín; Jaime Enríquez; Manuel Romero-Gómez; Rafael Bárcena; Javier Crespo; Raúl Andrade; Eva Martínez-Bauer; Ramón Pérez; Milagros Testillano; Ramón Planas; Ricard Solá; Manuel García-Bengoechea; Javier Garcia-Samaniego; Miguel Muñoz-Sánchez; Ricardo Moreno-Otero
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

4.  Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.

Authors:  Olav Dalgard; Kristian Bjøro; Kjell Block Hellum; Bjørn Myrvang; Ståle Ritland; Kjell Skaug; Nils Raknerud; Helge Bell
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

5.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Authors:  Thomas Berg; Michael von Wagner; Samer Nasser; Christoph Sarrazin; Tobias Heintges; Tilman Gerlach; Peter Buggisch; Tobias Goeser; Jens Rasenack; Gerd R Pape; Wolfgang E Schmidt; Birgit Kallinowski; Hartwig Klinker; Ulrich Spengler; Peter Martus; Ulrich Alshuth; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

6.  U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients.

Authors:  Samuel B Ho; Bashar Aqel; Eric Dieperink; Shanglei Liu; Lori Tetrick; Yngve Falck-Ytter; Charles DeComarmond; Coleman I Smith; Daniel P McKee; William Boyd; Clark C Kulig; Edmund J Bini; Marcos C Pedrosa
Journal:  Dig Dis Sci       Date:  2011-01-11       Impact factor: 3.199

Review 7.  The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon.

Authors:  L M Blatt; J M Davis; S B Klein; M W Taylor
Journal:  J Interferon Cytokine Res       Date:  1996-07       Impact factor: 2.607

8.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

9.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Authors:  John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

10.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391
View more
  1 in total

1.  Exome sequencing for the diagnosis of 46,XY disorders of sex development.

Authors:  Ruth M Baxter; Valerie A Arboleda; Hane Lee; Hayk Barseghyan; Margaret P Adam; Patricia Y Fechner; Renee Bargman; Catherine Keegan; Sharon Travers; Susan Schelley; Louanne Hudgins; Revi P Mathew; Heather J Stalker; Roberto Zori; Ora K Gordon; Leigh Ramos-Platt; Anna Pawlikowska-Haddal; Ascia Eskin; Stanley F Nelson; Emmanuèle Délot; Eric Vilain
Journal:  J Clin Endocrinol Metab       Date:  2014-11-10       Impact factor: 5.958
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.